DK0464845T3 - Pyrrolderivater - Google Patents

Pyrrolderivater

Info

Publication number
DK0464845T3
DK0464845T3 DK91111221.7T DK91111221T DK0464845T3 DK 0464845 T3 DK0464845 T3 DK 0464845T3 DK 91111221 T DK91111221 T DK 91111221T DK 0464845 T3 DK0464845 T3 DK 0464845T3
Authority
DK
Denmark
Prior art keywords
pyrrole
hyperlipoproteinemia
hypercholesterolemia
hmg
atherosclerosis
Prior art date
Application number
DK91111221.7T
Other languages
English (en)
Inventor
Kentaro Hirai
Teruyuki Ishiba
Haruo Koike
Nasamichi Watanabe
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Application granted granted Critical
Publication of DK0464845T3 publication Critical patent/DK0464845T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK91111221.7T 1990-07-05 1991-07-05 Pyrrolderivater DK0464845T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP17856490 1990-07-05

Publications (1)

Publication Number Publication Date
DK0464845T3 true DK0464845T3 (da) 1996-06-24

Family

ID=16050690

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91111221.7T DK0464845T3 (da) 1990-07-05 1991-07-05 Pyrrolderivater

Country Status (10)

Country Link
US (1) US5128366A (da)
EP (1) EP0464845B1 (da)
JP (1) JP3068665B2 (da)
KR (1) KR0167781B1 (da)
AT (1) ATE138909T1 (da)
CA (1) CA2046146C (da)
DE (1) DE69119979T2 (da)
DK (1) DK0464845T3 (da)
ES (1) ES2090177T3 (da)
GR (1) GR3020689T3 (da)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687146B1 (fr) * 1992-02-12 1994-04-01 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
DE4243279A1 (de) * 1992-12-21 1994-06-23 Bayer Ag Substituierte Triole
US6376476B1 (en) * 1996-12-13 2002-04-23 Zymogenetics Corporation Isoprenoid pathway inhibitors for stimulating bone growth
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6962999B2 (en) 2001-07-25 2005-11-08 Pharmacore, Inc. Process for preparing unsymmetrical biaryls and alkylated aromatic compounds from arylnitriles
JP5547865B2 (ja) * 2003-10-29 2014-07-16 ワイス・エルエルシー アプリンドルおよびその誘導体を含む持続放出型医薬組成物
JP5173192B2 (ja) 2004-09-30 2013-03-27 武田薬品工業株式会社 プロトンポンプ阻害薬
KR101115857B1 (ko) 2005-08-30 2012-04-12 다케다 야쿠힌 고교 가부시키가이샤 산 분비 억제제로서 1-헤테로시클릴술포닐, 2-아미노메틸,5-(헤테로-) 아릴 치환된 1-ｈ-피롤 유도체
US8933105B2 (en) 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
KR100856133B1 (ko) * 2008-01-11 2008-09-03 조동옥 아토르바스타틴의 개선된 제조방법
NZ591793A (en) 2008-08-27 2012-11-30 Takeda Pharmaceutical Substituted 1-(4-fluoro-5-(2-fluoropyridin-3-yl)-1-((pyrindin-2-yl)sulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine compounds
EP3698797A1 (en) 2017-10-16 2020-08-26 Tsinghua University Mevalonic acid pathway inhibitor and pharmaceutical composition thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598775B2 (en) * 1985-10-25 1990-07-05 Sandoz Ag Heterocyclic analogs of mevalonolactone
NO881411L (no) * 1987-04-14 1988-10-17 Bayer Ag Substituerte pyrroler.
IT1215578B (it) * 1987-06-24 1990-02-14 Roussel Maestretti Spa Derivati di 1-arilsolfonil1,5-diidro 2h-pirrol 2-one, loro procedimento di preparazione e loro applicazione come sostanze medicinali.
DE3722806A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-hept-6-ensaeuren, 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-heptansaeuren, ihre entsprechenden (delta)-lactone und salze, verfahren zu ihrer herstellung ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis

Also Published As

Publication number Publication date
EP0464845B1 (en) 1996-06-05
DE69119979T2 (de) 1996-10-24
ATE138909T1 (de) 1996-06-15
US5128366A (en) 1992-07-07
KR0167781B1 (ko) 1999-01-15
ES2090177T3 (es) 1996-10-16
CA2046146A1 (en) 1992-01-06
CA2046146C (en) 1997-02-25
KR920002536A (ko) 1992-02-28
JP3068665B2 (ja) 2000-07-24
GR3020689T3 (en) 1996-10-31
EP0464845A1 (en) 1992-01-08
DE69119979D1 (de) 1996-07-11
JPH04352767A (ja) 1992-12-07

Similar Documents

Publication Publication Date Title
HU0004863D0 (da)
DE69430279D1 (de) Pyrimidinverbindungen und ihre Verwendung als Pharmazeutika
DE69431458D1 (de) Echtheitsüberprüfung von Gegenständen
DE69119979D1 (de) Pyrrolderivate
EP0677036A4 (en) PRODUCTION OF ODOR-FREE TETRAHYDROISOCUMULATES.
MX9303594A (es) Oximas piridino, pirrolidino y azepino substituidas utiles como agentes antiateroscleroticos y antihipercolesterolemicos.
FI934223A0 (fi) Heterocykliscykliska aminderivat
ATE235236T1 (de) Unsubstituierte polydiallylaminen zur behandlung von hypercholesterolemia
NO930615D0 (no) Hypoglykemiske hydroksyurinstoffderivater
DE59708471D1 (de) Stabilisierung von Metallkonjugaten
DE69313846D1 (de) Vielseitiger, doppelt wirkender müllbehälterdeckel
EP0529854A3 (en) Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as hmg-coa reductase inhibitors
DE69407902D1 (de) Verstärkungsstufe und Oszillator
GR880100332A (el) ΑΝΑΣΤΟΛΕΙΣ ΤΗΣ ΡΕΔΟΥΚΤΑΣΗΣ HMG-CοA ΠΟΥ ΠΕΡΙΕΧΕΙ ΦΩΣΦΟΡΟ,ΝΕΑ ΕΝΔΙΑΜΕΣΑ ΚΑΙ ΜΕΘΟΔΟΣ
DE69510729D1 (de) Suspensionskonzentrat von insektiziden und akariziden Arylpyrrolen
DE59507596D1 (de) Verbindung von Backrohr und Backrohr-Aufnahmerahmen
FI931337L (fi) Uracilreduktasinaktivatorer
MY118381A (en) Statin-carboxyalkylether combinations
NO996206L (no) Farnesyltransferase inhibitorer i kombinasjon med HMG COA reduktase inhibitorer for behandling av cancer
FI893004A7 (fi) 5-oksygenoituja HMG-CoA-reduktaasi-inhibiittoreita
NO905291D0 (no) Fremgangsmaate for behandling av sinkholdige biprodukter og avfallsmaterialer.
DE69103919D1 (de) Diaminoverbindungen und Vorstufe dafür.
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
IT1255470B (it) Composti attivi come inibitori dell'enzima hmg-coa reduttasi
NO923862L (no) Inhibitorer for hmg-coa-reduktase